Skip to main content

Table 1 Demographic and Clinical Characteristics

From: Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q™), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women

Item

Enrolled (N = 104)

Age (years) mean (SD)

65.1 (10.3)

Race n (%)

 

   White

67 (64.4%)

   Black

1 (1.0%)

   Hispanic

36 (34.6%)

Living Situation

 

   Living alone

25 (24.0%)

   Living with another

77 (74.0%)

   Other

2 (1.9%)

Work Status

 

   Full-time

17 (16.3%)

   Part-time

19 (18.3%)

   Currently not working at a paid job

61 (58.7%)

   Other

7 (6.7%)

Education (highest level completed)

 

   Elementary

4 (3.8%)

   High school

38 (36.5%)

   Some college

31 (29.8%)

   College degree

19 (18.3%)

   Postgraduate

10 (9.6%)

   Other

2 (1.9%)

Time since diagnosis (years), mean ± SD

6.4 ± 7.0

No Health Insurance

16 (15.4%)

Time since first starting prescription meds for osteoporosis (bisphosphonates)

 

   < 3 months ago

7 (6.7%)

   > 3 months – 1 year

14 (13.5%)

   > 1 – 3 years ago

35 (33.7%)

   > 3 years

48 (46.2%)

Current Osteoporosis Treatment 1

 

   Weekly alendronate

61 (59%)

   Daily alendronate

13 (13%)

   Weekly risendronate

21 (20%)

   Daily risendronate

6 (6%)

Experienced at least 1 fracture since menopause n (%)

27 (26.0%)

Comorbid conditions n (%)

 

   Angina

3 (2.9%)

   Arthritis

59 (56.7%)

   COPD

6 (5.8%)

   Congestive heart failure

3 (2.9%)

   Depression

17 (16.3%)

   Hypertension

32 (30.8%)

   Other

26 (25.0%)

  1. 1Missing medication data for 1 subject; missing medication frequency data for 2 risedronate subjects.